arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IGC Pharma, Inc.

IGC
$0.29 0.00 (+1.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

IGC Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $29.1M
Dividend Yield
Revenue Growth -19.2%
Op. Margin None
ROIC -45.4%
FCF / Share $-0.01
Trailing P/E
Price / Book 4.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$265.00K
↓ -19.2%
Net Income Profit after all expenses
$-2.94M
↓ -83.6%
Operating Margin Operating profit as % of sales
-427.2%
↓ -1411.0%
FCF / Share Free cash flow per share
$-0.01
↑ +20.8%
Long-Term Debt Long-term obligations
$134.00K
↑ +1.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
7
Financial Health
47
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 66 quarters